New and Improved Treatment Options for Olfactory Loss (CME)
2019 AAO-HNSF Annual Meeting & OTO Experience
Keyword(s)
olfactory loss, translational studies
Patients who have lost their smell and taste are desperate for help, but unfortunately every year millions are told by their physicians that there is nothing that can be done to help them. This is certainly no longer the case. This panel will provide the general otolaryngologist with the practical ability to offer hope and real therapeutic options to their patients with this devastating problem. Learn what benefit current treatment options provide, which once-popular remedies have since been disproven, and find out what translational studies are underway to bring the latest cutting-edge research to your patient in the office.
Credits
CME:1.0, MOC:1.0
Description
Patients who have lost their smell and taste are desperate for help, but unfortunately every year millions are told by their physicians that there is nothing that can be done to help them. This is certainly no longer the case. This panel will provide the general otolaryngologist with the practical ability to offer hope and real therapeutic options to their patients with this devastating problem. Learn what benefit current treatment options provide, which once-popular remedies have since been disproven, and find out what translational studies are underway to bring the latest cutting-edge research to your patient in the office.Learning Objectives: 1. Appraise the latest proven treatment options for your patients with olfactory loss. 2. Determine which treatment options have been disproven to help patients with olfactory loss. 3. Discuss the newest research and demonstrate how to direct your patients with olfactory loss to sites where translational studies are underway.Faculty: Zara Patel, MD(Honoraria: Intersect ENT; Consulting Fees: Medtronic; Stryker; Optinose), Eric Holbrook, MD(Expert Witness: Margol & Margol; Leadership Role: ARS; Consulting Fees: 480 Biomedical), Justin Turner, MD, PhD(Research funding: American Rhinologic Society; NIH; Consulting Fees: Intersect ENT), Bradley Goldstein, MD, PhD(Did Not Disclose).
